Structural basis for the action of the drug trametinib at KSR-bound MEK

Zaigham M. Khan, Alexander M. Real, William M. Marsiglia, Arthur Chow, Mary E. Duffy, Jayasudhan R. Yerabolu, Alex P. Scopton and Arvin C. Dar ()
Additional contact information
Zaigham M. Khan: The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Alexander M. Real: The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
William M. Marsiglia: The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Arthur Chow: The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Mary E. Duffy: The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Jayasudhan R. Yerabolu: The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Alex P. Scopton: The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Arvin C. Dar: The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Nature, 2020, vol. 588, issue 7838, 509-514

Abstract: Abstract The MAPK/ERK kinase MEK is a shared effector of the frequent cancer drivers KRAS and BRAF that has long been pursued as a drug target in oncology1, and more recently in immunotherapy2,3 and ageing4. However, many MEK inhibitors are limited owing to on-target toxicities5–7 and drug resistance8–10. Accordingly, a molecular understanding of the structure and function of MEK within physiological complexes could provide a template for the design of safer and more effective therapies. Here we report X-ray crystal structures of MEK bound to the scaffold KSR (kinase suppressor of RAS) with various MEK inhibitors, including the clinical drug trametinib. The structures reveal an unexpected mode of binding in which trametinib directly engages KSR at the MEK interface. In the bound complex, KSR remodels the prototypical allosteric pocket of the MEK inhibitor, thereby affecting binding and kinetics, including the drug-residence time. Moreover, trametinib binds KSR–MEK but disrupts the related RAF–MEK complex through a mechanism that exploits evolutionarily conserved interface residues that distinguish these sub-complexes. On the basis of these insights, we created trametiglue, which limits adaptive resistance to MEK inhibition by enhancing interfacial binding. Our results reveal the plasticity of an interface pocket within MEK sub-complexes and have implications for the design of next-generation drugs that target the RAS pathway.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41586-020-2760-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:588:y:2020:i:7838:d:10.1038_s41586-020-2760-4

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-2760-4

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().